Novo Nordisk teams with OpenAI

Drug discovery is a search problem: researchers sift through huge piles of biology, chemistry and trial data to find a few molecules worth testing in people. Novo Nordisk said on April 14 it will use OpenAI’s tools to speed that search across obesity and diabetes work. (biospace.com) Novo Nordisk said the partnership will start with a pilot in research and development, manufacturing and commercial teams, with full integration across the company planned by the end of 2026. The company said the rollout includes “strict data governance and human oversight.” (pharmaceutical-technology.com) OpenAI’s models will be used to analyze large scientific and operational datasets, help identify promising drug targets and compounds, and support work beyond the lab in supply chain and distribution. Novo Nordisk and OpenAI did not disclose financial terms on April 14. (cnbc.com) Obesity and diabetes drug development runs on years of experiments, failed candidates and expensive clinical trials. Companies are increasingly using artificial intelligence systems as pattern-finding tools to narrow the field before they spend money on animal studies and human testing. (euronews.com) The timing is tied to a hard commercial race. Reuters reported that Novo Nordisk has fallen behind Eli Lilly in the weight-loss market, even as Novo sells Wegovy for obesity and Ozempic for diabetes and obesity-related demand keeps growing. (finance.yahoo.com) Novo Nordisk is not starting from zero on artificial intelligence. Bloomberg reported that the OpenAI deal adds to Novo’s existing artificial-intelligence work, including a research-focused partnership with Nvidia announced in 2025. (bloomberg.com) The company said the new partnership is also meant to train employees to use the tools, not just plug software into research. MarketWatch reported that Novo framed the deal as a way to help develop medicines faster while also helping upskill its workforce. (marketwatch.com) Investors initially welcomed the announcement. Reports from MarketWatch and other outlets said Novo Nordisk shares rose in early trading on April 14 after the company disclosed the OpenAI partnership. (marketwatch.com) For Novo Nordisk, the immediate test is simple: whether a tool built to find patterns in language and data can shorten the long, expensive path to the next obesity or diabetes medicine. The company said the goal is to bring “new and better treatment options to patients faster.” (cnbc.com)